CAMK2G and PEA15 |
calcium/calmodulin dependent protein kinase II gamma |
proliferation and apoptosis adaptor protein 15 |
- CaMK IV-mediated phosphorylation of CREB
- HSF1-dependent transactivation
- Trafficking of AMPA receptors
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- Ras activation upon Ca2+ influx through NMDA receptor
- Phase 0 - rapid depolarisation
- Ion homeostasis
- RAF activation
- RAF/MAP kinase cascade
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Interferon gamma signaling
- Regulation of MECP2 expression and activity
- Ion transport by P-type ATPases
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
- Signaling downstream of RAS mutants
|
- RAF-independent MAPK1/3 activation
- RAF/MAP kinase cascade
|
- Bosutinib
- 1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
|
|
|
CAMK2G and CREM |
calcium/calmodulin dependent protein kinase II gamma |
cAMP responsive element modulator |
- CaMK IV-mediated phosphorylation of CREB
- HSF1-dependent transactivation
- Trafficking of AMPA receptors
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- Ras activation upon Ca2+ influx through NMDA receptor
- Phase 0 - rapid depolarisation
- Ion homeostasis
- RAF activation
- RAF/MAP kinase cascade
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Interferon gamma signaling
- Regulation of MECP2 expression and activity
- Ion transport by P-type ATPases
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
- Signaling downstream of RAS mutants
|
|
- Bosutinib
- 1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
|
|
|
CAMK2G and STAT1 |
calcium/calmodulin dependent protein kinase II gamma |
signal transducer and activator of transcription 1 |
- CaMK IV-mediated phosphorylation of CREB
- HSF1-dependent transactivation
- Trafficking of AMPA receptors
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- Ras activation upon Ca2+ influx through NMDA receptor
- Phase 0 - rapid depolarisation
- Ion homeostasis
- RAF activation
- RAF/MAP kinase cascade
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Interferon gamma signaling
- Regulation of MECP2 expression and activity
- Ion transport by P-type ATPases
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
- Signaling downstream of RAS mutants
|
- Interleukin-6 signaling
- ISG15 antiviral mechanism
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-20 family signaling
- Regulation of RUNX2 expression and activity
- Interleukin-35 Signalling
- Interleukin-9 signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- Interleukin-27 signaling
- Interleukin-21 signaling
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Growth hormone receptor signaling
|
- Bosutinib
- 1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
|
|
- Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
- IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency
|
CAMK2G and SMAD2 |
calcium/calmodulin dependent protein kinase II gamma |
SMAD family member 2 |
- CaMK IV-mediated phosphorylation of CREB
- HSF1-dependent transactivation
- Trafficking of AMPA receptors
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- Ras activation upon Ca2+ influx through NMDA receptor
- Phase 0 - rapid depolarisation
- Ion homeostasis
- RAF activation
- RAF/MAP kinase cascade
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Interferon gamma signaling
- Regulation of MECP2 expression and activity
- Ion transport by P-type ATPases
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
- Signaling downstream of RAS mutants
|
- Signaling by NODAL
- Signaling by NODAL
- Signaling by Activin
- Downregulation of TGF-beta receptor signaling
- TGF-beta receptor signaling activates SMADs
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- SMAD2/3 Phosphorylation Motif Mutants in Cancer
- SMAD4 MH2 Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- TGFBR1 KD Mutants in Cancer
- Transcriptional regulation of pluripotent stem cells
- Ub-specific processing proteases
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- FOXO-mediated transcription of cell cycle genes
- FOXO-mediated transcription of cell cycle genes
|
- Bosutinib
- 1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
|
|
|
CAMK2G and SMAD4 |
calcium/calmodulin dependent protein kinase II gamma |
SMAD family member 4 |
- CaMK IV-mediated phosphorylation of CREB
- HSF1-dependent transactivation
- Trafficking of AMPA receptors
- Unblocking of NMDA receptors, glutamate binding and activation
- Unblocking of NMDA receptors, glutamate binding and activation
- CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde
- Ras activation upon Ca2+ influx through NMDA receptor
- Phase 0 - rapid depolarisation
- Ion homeostasis
- RAF activation
- RAF/MAP kinase cascade
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Interferon gamma signaling
- Regulation of MECP2 expression and activity
- Ion transport by P-type ATPases
- Assembly and cell surface presentation of NMDA receptors
- Negative regulation of NMDA receptor-mediated neuronal transmission
- Long-term potentiation
- Signaling downstream of RAS mutants
|
- Signaling by NODAL
- Signaling by Activin
- Signaling by BMP
- TGF-beta receptor signaling activates SMADs
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- Downregulation of SMAD2/3:SMAD4 transcriptional activity
- SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
- SMAD4 MH2 Domain Mutants in Cancer
- SMAD2/3 MH2 Domain Mutants in Cancer
- Transcriptional regulation of pluripotent stem cells
- Ub-specific processing proteases
- RUNX2 regulates bone development
- RUNX3 regulates CDKN1A transcription
- RUNX3 regulates BCL2L11 (BIM) transcription
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- FOXO-mediated transcription of cell cycle genes
- FOXO-mediated transcription of cell cycle genes
|
- Bosutinib
- 1-tert-butyl-3-(3-methylbenzyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
|
|
|
- Colorectal cancer
- Hereditary hemorrhagic telangiectasia (HHT)
- Pancreatic cancer
- Juvenile polyposis syndrome
|
CANX and LRP1 |
calnexin |
LDL receptor related protein 1 |
- Assembly of Viral Components at the Budding Site
- MHC class II antigen presentation
- Interleukin-35 Signalling
- Calnexin/calreticulin cycle
- Interleukin-27 signaling
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
- Antigen Presentation: Folding, assembly and peptide loading of class I MHC
|
- Scavenging of heme from plasma
- Retinoid metabolism and transport
|
- Antihemophilic factor, human recombinant
- Tenecteplase
- Calcium Citrate
- Calcium Phosphate
|
- Antihemophilic factor, human recombinant
- Tenecteplase
- Coagulation Factor IX (Recombinant)
- Coagulation Factor IX Human
|
|
|
CAPN1 and MAPT |
calpain 1 |
microtubule associated protein tau |
- Degradation of the extracellular matrix
- Degradation of the extracellular matrix
- Neutrophil degranulation
- Formation of the cornified envelope
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
- Caspase-mediated cleavage of cytoskeletal proteins
|
- N-[N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-Butyl]-Guanidine
- CBZ-LEU-LEU-TYR-CH2F
- (2S)-4-METHYL-2-(3-PHENYLTHIOUREIDO)-N-((3S)-TETRAHYDRO-2-HYDROXY-3-FURANYL)PENTANAMIDE
|
- Lansoprazole
- Astemizole
- Paclitaxel
- Docetaxel
|
|
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
|
CAPN2 and MAPT |
calpain 2 |
microtubule associated protein tau |
- Degradation of the extracellular matrix
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
- Caspase-mediated cleavage of cytoskeletal proteins
|
|
- Lansoprazole
- Astemizole
- Paclitaxel
- Docetaxel
|
|
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
|
CAPN2 and TNS1 |
calpain 2 |
tensin 1 |
- Degradation of the extracellular matrix
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
- Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
|
|
|
|
|
|
CASP1 and IL37 |
caspase 1 |
interleukin 37 |
- NOD1/2 Signaling Pathway
- Interleukin-1 processing
- TP53 Regulates Transcription of Caspase Activators and Caspases
- The NLRP3 inflammasome
- The AIM2 inflammasome
- The IPAF inflammasome
- Interleukin-37 signaling
- Purinergic signaling in leishmaniasis infection
|
- Interleukin-37 signaling
- Interleukin-18 signaling
|
- Minocycline
- Pralnacasan
- LAX-101
- Emricasan
- VX-765
- 1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE
- Z-Val-Ala-Asp fluoromethyl ketone
- 3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID
|
|
|
|
CASP1 and MAPT |
caspase 1 |
microtubule associated protein tau |
- NOD1/2 Signaling Pathway
- Interleukin-1 processing
- TP53 Regulates Transcription of Caspase Activators and Caspases
- The NLRP3 inflammasome
- The AIM2 inflammasome
- The IPAF inflammasome
- Interleukin-37 signaling
- Purinergic signaling in leishmaniasis infection
|
- Caspase-mediated cleavage of cytoskeletal proteins
|
- Minocycline
- Pralnacasan
- LAX-101
- Emricasan
- VX-765
- 1-METHYL-3-TRIFLUOROMETHYL-1H-THIENO[2,3-C]PYRAZOLE-5-CARBOXYLIC ACID (2-MERCAPTO-ETHYL)-AMIDE
- Z-Val-Ala-Asp fluoromethyl ketone
- 3-{6-[(8-HYDROXY-QUINOLINE-2-CARBONYL)-AMINO]-2-THIOPHEN-2-YL-HEXANOYLAMINO}-4-OXO-BUTYRI ACID
|
- Lansoprazole
- Astemizole
- Paclitaxel
- Docetaxel
|
|
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
|
CASP2 and DSP |
caspase 2 |
desmoplakin |
- NOD1/2 Signaling Pathway
- NADE modulates death signalling
- TP53 Regulates Transcription of Caspase Activators and Caspases
|
- Apoptotic cleavage of cell adhesion proteins
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
|
|
|
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Naxos disease and Carvajal syndrome
- Striate palmoplantar keratoderma
- Skin fragility-woolly hair syndrome
- Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
|
CASP3 and MAPT |
caspase 3 |
microtubule associated protein tau |
- Activation of caspases through apoptosome-mediated cleavage
- SMAC (DIABLO) binds to IAPs
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- Apoptotic cleavage of cellular proteins
- SMAC, XIAP-regulated apoptotic response
- Apoptosis induced DNA fragmentation
- Degradation of the extracellular matrix
- Signaling by Hippo
- NADE modulates death signalling
- Stimulation of the cell death response by PAK-2p34
- Caspase-mediated cleavage of cytoskeletal proteins
- Apoptotic cleavage of cell adhesion proteins
- Caspase activation via Dependence Receptors in the absence of ligand
- Caspase activation via Dependence Receptors in the absence of ligand
- Other interleukin signaling
|
- Caspase-mediated cleavage of cytoskeletal proteins
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- Emricasan
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
- Lansoprazole
- Astemizole
- Paclitaxel
- Docetaxel
|
|
- Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
- Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
- Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
|
CASP3 and SOCS5 |
caspase 3 |
suppressor of cytokine signaling 5 |
- Activation of caspases through apoptosome-mediated cleavage
- SMAC (DIABLO) binds to IAPs
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- Apoptotic cleavage of cellular proteins
- SMAC, XIAP-regulated apoptotic response
- Apoptosis induced DNA fragmentation
- Degradation of the extracellular matrix
- Signaling by Hippo
- NADE modulates death signalling
- Stimulation of the cell death response by PAK-2p34
- Caspase-mediated cleavage of cytoskeletal proteins
- Apoptotic cleavage of cell adhesion proteins
- Caspase activation via Dependence Receptors in the absence of ligand
- Caspase activation via Dependence Receptors in the absence of ligand
- Other interleukin signaling
|
- Interleukin-4 and Interleukin-13 signaling
- Neddylation
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- Emricasan
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
|
|
|
CASP3 and PICALM |
caspase 3 |
phosphatidylinositol binding clathrin assembly protein |
- Activation of caspases through apoptosome-mediated cleavage
- SMAC (DIABLO) binds to IAPs
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- Apoptotic cleavage of cellular proteins
- SMAC, XIAP-regulated apoptotic response
- Apoptosis induced DNA fragmentation
- Degradation of the extracellular matrix
- Signaling by Hippo
- NADE modulates death signalling
- Stimulation of the cell death response by PAK-2p34
- Caspase-mediated cleavage of cytoskeletal proteins
- Apoptotic cleavage of cell adhesion proteins
- Caspase activation via Dependence Receptors in the absence of ligand
- Caspase activation via Dependence Receptors in the absence of ligand
- Other interleukin signaling
|
- Golgi Associated Vesicle Biogenesis
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- Emricasan
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
|
|
|
CASP3 and PKN2 |
caspase 3 |
protein kinase N2 |
- Activation of caspases through apoptosome-mediated cleavage
- SMAC (DIABLO) binds to IAPs
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- Apoptotic cleavage of cellular proteins
- SMAC, XIAP-regulated apoptotic response
- Apoptosis induced DNA fragmentation
- Degradation of the extracellular matrix
- Signaling by Hippo
- NADE modulates death signalling
- Stimulation of the cell death response by PAK-2p34
- Caspase-mediated cleavage of cytoskeletal proteins
- Apoptotic cleavage of cell adhesion proteins
- Caspase activation via Dependence Receptors in the absence of ligand
- Caspase activation via Dependence Receptors in the absence of ligand
- Other interleukin signaling
|
- RHO GTPases activate PKNs
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- Emricasan
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
|
|
|
CASP3 and BCAR1 |
caspase 3 |
BCAR1 scaffold protein, Cas family member |
- Activation of caspases through apoptosome-mediated cleavage
- SMAC (DIABLO) binds to IAPs
- SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
- Apoptotic cleavage of cellular proteins
- SMAC, XIAP-regulated apoptotic response
- Apoptosis induced DNA fragmentation
- Degradation of the extracellular matrix
- Signaling by Hippo
- NADE modulates death signalling
- Stimulation of the cell death response by PAK-2p34
- Caspase-mediated cleavage of cytoskeletal proteins
- Apoptotic cleavage of cell adhesion proteins
- Caspase activation via Dependence Receptors in the absence of ligand
- Caspase activation via Dependence Receptors in the absence of ligand
- Other interleukin signaling
|
- Downstream signal transduction
- p130Cas linkage to MAPK signaling for integrins
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
|
- Minocycline
- 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
- Emricasan
- 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
- methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
- 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
- [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
- 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
- (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
- N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
|
|
|
|
CASP4 and DSP |
caspase 4 |
desmoplakin |
|
- Apoptotic cleavage of cell adhesion proteins
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
|
|
|
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Naxos disease and Carvajal syndrome
- Striate palmoplantar keratoderma
- Skin fragility-woolly hair syndrome
- Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
|
CASP4 and IL37 |
caspase 4 |
interleukin 37 |
|
- Interleukin-37 signaling
- Interleukin-18 signaling
|
|
|
|
|
CASP6 and DSP |
caspase 6 |
desmoplakin |
- Apoptotic cleavage of cellular proteins
- Caspase-mediated cleavage of cytoskeletal proteins
- Breakdown of the nuclear lamina
- TP53 Regulates Transcription of Caspase Activators and Caspases
|
- Apoptotic cleavage of cell adhesion proteins
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
|
|
|
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Naxos disease and Carvajal syndrome
- Striate palmoplantar keratoderma
- Skin fragility-woolly hair syndrome
- Epidermolysis bullosa simplex, including: Epidermolysis bullosa simplex, Dowling-Meara type (EBS-DM); Epidermolysis bullosa simplex, Koebner type (EBS-K); Epidermolysis bullosa simplex, Weber-Cockayne type (EBS-WC); Epidermolysis bullosa simplex with mottled pigmentation (EBS-MP); Epidermolysis bullosa simplex with migratory circinate erythema; Epidermolysis bullosa simplex, recessive; Epidermolysis bullosa, lethal acantholytic
|